Kapitalradar

Swiss capital increases, read from the official gazette and scored for financing rounds.

updated every weekdayrelease r9data as of 8 Oct 2026

↺ Try a rewind: Soverli AG on 24 Sep 2025, 83 days before the round was announced

Release evaluation · 7 Oct 2026 · does not rewind · rules + Claude: precision 2%–100% (n=17), recall 16/30 announced rounds · rules-only: precision 1%–99% (n=29), recall 18/30 announced rounds · Methodology

Published by 8 Oct 2026
Drag the red line through time · ← → a day · Shift+← → a week. Later days aren’t drawn: they haven’t been published yet.
1733Aug 25Sep 25Oct 25Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26

Scope · likely financings by canton

40 likely financings · 9 Sep 2026 – 8 Oct 2026 · the feed below shows one weekZH ✕ show all cantonsMap: Natural Earth

Likely financing
Looks like new money from outside investors: Claude, reading the entry and the rule signals, scores it 0.60 or higher.
Undecided
Some financing signals, not enough to call it: a score from 0.35 to below 0.60, or no usable score.
Capital increased
No sign of a financing round: the pre-filter found nothing to send to Claude, or Claude scored it below 0.35. Typical causes are converted loans, assets contributed in kind, reserves turned into capital or a conversion to an AG.
Confirmed round
A financing announcement on startupticker.ch names the company and matches this increase.

Published 5–8 Oct 2026 · canton ZH

21 capital increases · 8 shown
Showing: likely financings and confirmed rounds ▾
Show
Capital increases published 5–8 Oct 2026
CompanyStatusNominal share capital (CHF)
before → after		New shares, % of
post-step shares		Announced roundnot disclosed in the SHABSHAB publishedSource
SecureCell AGZH · Die Gesellschaft bezweckt die Entwicklung und Vermarktung von Technologien, Produkten und Dienstleistungen …SHAB publication HR02-1006777396Likely financingscore 0.62365’982.50 → 400’982.50New shares 8.7%8.7%—8 Oct 2026SHAB publication HR02-1006777396
My Tinnitus has gone AGZH · Die Gesellschaft bezweckt die Herstellung und den Vertrieb von Instrumentarien zur Behandlung von …SHAB publication HR02-1006776121Likely financingscore 0.60200’000 → 250’000New shares 20.0%20.0%—7 Oct 2026SHAB publication HR02-1006776121
SpineCo AGZH · Zweck der Gesellschaft ist die Entwicklung, die Produktion, der Verkauf und der Vertrieb von medizinischen …SHAB publication HR02-1006776077Likely financingscore 0.75100’000 → 122’801.50New shares — nominal value per share changed— nominal value per share changed—7 Oct 2026SHAB publication HR02-1006776077
Circleg AGZH · Die Gesellschaft bezweckt die Entwicklung und den Vertrieb von medizinischen und nicht medizinischen …SHAB publication HR02-1006776057Likely financingscore 0.92100’000 → 175’210.03New shares 42.9%42.9%—7 Oct 2026SHAB publication HR02-1006776057
PQ Technologies AGZH · Die Gesellschaft bezweckt die Erbringung von Compliance und Risk Dienst- und Serviceleistungen unter Einbezug …SHAB publication HR02-1006774640Likely financingscore 0.95100’000 → 129’629.50New shares 22.9%22.9%—6 Oct 2026SHAB publication HR02-1006774640
MYNERVA AGZH · Die Gesellschaft bezweckt die Entwicklung, Herstellung, den Vertrieb und den Verkauf von medizinischen …SHAB publication HR02-1006774630Likely financingscore 0.80118’318.56 → 122’743.33New shares 3.6%3.6%—6 Oct 2026SHAB publication HR02-1006774630
ONTRACK Biomedical AGZH · Die Gesellschaft bezweckt die Entwicklung, Herstellung und Vermarktung von biomedizinischen Reagenzien. Die …SHAB publication HR02-1006773225Likely financingscore 0.80100’000 → 132’231.38New shares 24.4%24.4%—5 Oct 2026SHAB publication HR02-1006773225
MEDIRAPP AGZH · Die Gesellschaft bezweckt die Entwicklung und Vermarktung von Software und AI Applikationen sowie …SHAB publication HR02-1006773211Likely financingscore 0.93102’564 → 135’944New shares 24.6%24.6%—5 Oct 2026SHAB publication HR02-1006773211

13 other capital increases published this week ▸